RapidPulse

Executive Summary

RapidPulse is a private, clinical-stage medical device company headquartered in San Francisco, dedicated to transforming outcomes for ischemic stroke patients. The company has developed an innovative device platform designed to improve revascularization rates and reduce procedural times, addressing the critical unmet need in acute stroke care. Founded in 2019, RapidPulse is currently advancing its technology through a pivotal clinical study, having recently initiated patient enrollment. The company's mission is to deliver results-driven innovation that can meaningfully impact the standard of care in stroke intervention. RapidPulse's progress in its pivotal trial represents a key inflection point, as successful outcomes could position the company for regulatory submissions and commercial launch. The stroke treatment market is large and growing, driven by aging populations and expanding treatment windows. However, as a private clinical-stage company, RapidPulse faces risks including enrollment delays, competitive technologies, and the need for additional capital. If the pivotal study meets its endpoints, RapidPulse could become a significant player in the neurovascular space, offering a differentiated solution to interventional neurologists.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Study Full Enrollment70% success
• Q2 2027Interim Efficacy Data Readout60% success
• TBDStrategic Partnership or Licensing Deal40% success